Amicus Therapeutics ownership disclosure: The filing reports that The Goldman Sachs Group, Inc. and affiliate Goldman Sachs & Co. LLC together hold 16,782,162.81 shares of Amicus common stock, representing 5.3% of the class, with shared voting and shared dispositive power reported.
The filing is a joint Schedule 13G statement executed by GS Group and Goldman Sachs & Co. LLC and includes exhibits identifying the reporting subsidiary relationship and a joint filing agreement.
Positive
None.
Negative
None.
Insights
Passive institutional holding disclosed; no change in control signaled.
The Schedule 13G lists 16,782,162.81 shares and 5.3% ownership with shared voting and dispositive power by Goldman Sachs reporting units. The form indicates a passive ownership filing rather than an active solicitation or control intent.
Dependencies include whether holdings are client‑segregated or managed accounts per Exhibit (99.3); subsequent amendments would show any material changes.
Disclosure clarifies beneficial ownership and allocation across Goldman Sachs units.
The filing attaches an exhibit describing that the securities are held by a broker‑dealer subsidiary and other reporting units, consistent with Rule 13d‑1(k) joint filings. It also disclaims beneficial ownership for certain client accounts per the Release cited.
Cash‑flow treatment and any trading intent are not described in the excerpt; future amendments would capture trading or schedule changes.
Key Figures
Shares reported:16,782,162.81 sharesPercent of class:5.3%CUSIP:03152W109+1 more
4 metrics
Shares reported16,782,162.81 sharesshared voting/dispositive power reported on Schedule 13G
Percent of class5.3%percent of outstanding common stock as reported on the cover page
CUSIP03152W109Amicus Therapeutics common stock identifier
Joint filing date04/24/2026date on Joint Filing Agreement and signatures
"the filing is a joint Schedule 13G statement executed by GS Group"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
AMICUS THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
03152W109
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
03152W109
1
Names of Reporting Persons
THE GOLDMAN SACHS GROUP, INC.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
16,781,792.81
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
16,782,162.81
9
Aggregate Amount Beneficially Owned by Each Reporting Person
16,782,162.81
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
HC, CO
SCHEDULE 13G
CUSIP Number(s):
03152W109
1
Names of Reporting Persons
GOLDMAN SACHS & CO. LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NEW YORK
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
16,781,792.81
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
16,782,162.81
9
Aggregate Amount Beneficially Owned by Each Reporting Person
16,782,162.81
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
BD, OO, IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
AMICUS THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
47 Hulfish Street,, Princeton, X1, 08542
Item 2.
(a)
Name of person filing:
THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)
Address or principal business office or, if none, residence:
The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)
Citizenship:
THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)
Title of class of securities:
Common Stock, par value $0.01 per share
(e)
CUSIP Number(s):
03152W109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See the response(s) to Item 9 on the attached cover page(s).
(b)
Percent of class:
See the response(s)to Item 11 on the attached cover page(s).
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See the response(s) to Item 5 on the attached cover page(s).
(ii) Shared power to vote or to direct the vote:
See the response(s) to Item 6 on the attached cover page(s).
(iii) Sole power to dispose or to direct the disposition of:
See the response(s) to Item 7 on the attached cover page(s).
(iv) Shared power to dispose or to direct the disposition of:
See the response(s) to Item 8 on the attached cover page(s).
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit (99.2)
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
THE GOLDMAN SACHS GROUP, INC.
Signature:
Name: Sam Prashanth
Name/Title:
Attorney-in-fact
Date:
04/24/2026
GOLDMAN SACHS & CO. LLC
Signature:
Name: Sam Prashanth
Name/Title:
Attorney-in-fact
Date:
04/24/2026
Exhibit Information
EXHIBIT (99.1)
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) promulgated under the Securities
Exchange Act of 1934, the undersigned agree to the joint filing of a Statement
on Schedule 13G (including any and all amendments thereto) with respect to the
Common Stock, par value $0.01 per share, of AMICUS THERAPEUTICS, INC.
and further agree to the filing of this agreement as an Exhibit thereto.
In addition, each party to this Agreement expressly authorizes each other party
to this Agreement to file on its behalf any and all amendments to such Statement
on Schedule 13G.
Date: 04/24/2026
THE GOLDMAN SACHS GROUP, INC.
By:/s/ Sam Prashanth
----------------------------------------
Name: Sam Prashanth
Title: Attorney-in-fact
GOLDMAN SACHS & CO. LLC
By:/s/ Sam Prashanth
----------------------------------------
Name: Sam Prashanth
Title: Attorney-in-fact
EXHIBIT (99.2)
ITEM 7 INFORMATION
The securities being reported on by The Goldman Sachs Group, Inc.
("GS Group"), as a parent holding company, are owned, or may be deemed to be
beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or
dealer registered under Section 15 of the Act and an investment adviser
registered under Section 203 of the Investment Advisers Act of 1940. Goldman
Sachs is a subsidiary of GS Group.
EXHIBIT (99.3)
ITEM 4 INFORMATION
*In accordance with the Securities and Exchange Commission Release No.
34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities
beneficially owned by certain operating units (collectively, the "Goldman Sachs
Reporting Units") of The Goldman Sachs Group, Inc. and its subsidiaries and
affiliates (collectively, "GSG"). This filing does not reflect securities, if
any, beneficially owned by any operating units of GSG whose ownership of
securities is disaggregated from that of the Goldman Sachs Reporting Units in
accordance with the Release. The Goldman Sachs Reporting Units disclaim
beneficial ownership of the securities beneficially owned by (i) any client
accounts with respect to which the Goldman Sachs Reporting Units or their
employees have voting or investment discretion or both, or with respect to
which there are limits on their voting or investment authority or both and
(ii) certain investment entities of which the Goldman Sachs Reporting Units
act as the general partner, managing general partner or other manager, to the
extent interests in such entities are held by persons other than the Goldman
Sachs Reporting Units.
What stake does Goldman Sachs report in AMICUS THERAPEUTICS (FOLD)?
Goldman Sachs reports 16,782,162.81 shares, equal to 5.3% of Amicus Therapeutics common stock, with shared voting and dispositive power as shown on the cover page.
Is this Schedule 13G indicating active control or a passive investment?
This filing is a joint Schedule 13G, which typically reports passive institutional holdings; the filing does not state an intent to seek control or solicit proxies.
Which Goldman entities are named as reporting persons in the 13G?
The filing names The Goldman Sachs Group, Inc. and affiliate Goldman Sachs & Co. LLC, both with principal business offices at 200 West Street, New York, NY.
Do the exhibits explain where the shares are held or whether clients are involved?
Yes; Exhibit (99.2) and (99.3) state the securities are held by Goldman Sachs Reporting Units and disclaim beneficial ownership for certain client accounts and disaggregated operating units.
When was the joint filing agreement executed?
The joint filing agreement (Exhibit (99.1)) is dated 04/24/2026 and is signed by Sam Prashanth as attorney‑in‑fact for both filing parties.
